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- 93 lightening soaps and 98 creams were purchased in West Africa and Canada.  
- Mercury, hydroquinone and clobetasol propionate were measured. 
- 68 to 84% of all creams exceeded regulatory guidelines. 




Skin lightening products are types of cosmetics (creams, gels, lotions and soaps) applied voluntarily on 
skin. Several of these products contain a variety of active ingredients that are highly toxic. Among those 
toxic agents, the present study focuses on mercury, hydroquinone, and clobetasol propionate. Out of the 
93 lightening soaps and 98 creams purchased in large city markets in sub-Saharan West Africa and in 
small ethnic shops in Canada, 68 to 84% of all creams and 7.5 to 65% of all soaps exceeded regulatory 
guidelines for at least one active ingredient when considering different regulations. Mercury was found 
in high concentrations mainly in soaps, while hydroquinone and clobetasol propionate concentrations 
exceeded US FDA standards in some creams for all countries included in our study. Concentrations of 
the three compounds declared on labels of soaps and creams usually did not correspond to 
concentrations actually measured, particularly for mercury and hydroquinone. Overall, our results 
indicate that most studied skin-lightening products are potentially toxic and that product labels are 
frequently inaccurate with respect to the presence of toxic agents.  
 






Skin lightening products are types of cosmetics sold as creams, gels, lotions and soaps that are applied 
voluntarily on skin. In many African and Asian countries, and in many large cities worldwide where 
communities from these countries reside, the use of skin lightening products is becoming increasingly 
popular (Lewis et al., 2012, Uram et al., 2010, Mahe et al., 2007, Petit et al., 2006). Previous studies 
conducted in major cities of some West African countries have shown that a significant proportion 
(between 26 and 67%) of adult females used these products daily to lighten their skin (Dadzie and Petit, 
2009). Several of these products claim to contain a variety of active ingredients that are highly toxic 
(Bocca et al., 2014, Al-Saleh et al., 2012, Mahe et al., 2007). Among those toxic agents, the present 
study focuses on mercury, hydroquinone, and clobetasol propionate. We selected these three ingredients 
amongst others because they are amongst the most toxic and most used agents in lightening products, 
and they are often subject to regulations (Groupe Thématique 'Peau Noire' de la Société Française de 
Dermatologie, 2011, Dadzie and Petit, 2009, Del Giudice et al., 2003). 
Inorganic mercury (e.g. mercurous chloride, ammoniated mercury, mercurous oxides or mercuric 
chloride) is the form of mercury commonly found in skin lightening products (Olumide et al., 2008, 
Palmer et al., 2000). It is a very toxic element that can inhibit melanin production by competing with 
copper in tyrosinase, resulting in the appearance of paler skin (Engler, 2005, Denton et al., 1952). Its 
cutaneous absorption is carried out either through the epidermis or through the sweat glands, the 
sebaceous glands or hair follicles, and significant dermal absorption can occur depending on different 
factors such as hydration of the stratum corneum and the frequency of application of these products on 
the skin. Urinary excretion is the major route of elimination (Chan, 2011, Copan et al., 2015, Sin and 
Tsang, 2003). Inorganic Hg concentrates mainly in the kidney, in particular in the tubular region where 
lesions have been observed after acute oral intake of Hg2+ salts (Al-Saleh et al., 2005). With repeated 
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applications, the cumulative effect of prolonged low-dose exposure may lead to nephrotoxic effects, 
proteinuria and nephritis (Al-Saleh et al., 2005, Engler, 2005). The central nervous system can also be 
affected by inorganic Hg under certain conditions. In fact, although penetration of the blood-brain 
barrier by inorganic mercury is poor, prolonged exposure can result in central nervous system 
accumulation and neurotoxicity (Copan et al., 2015, Chan, 2011). 
Hydroquinone is a major benzene metabolite widely used in skin lightening products. It is a well-known 
hepatotoxic and carcinogenic agent (Enguita and Leitao, 2013). In contact with skin, hydroquinone acts 
as an alternate substrate of tyrosinase. In the place of tyrosine, which should be transformed into 
melanin, hydroquinone metabolizes into quinones and free radicals. These radicals can then attack 
melanocyte membranes exerting a cytotoxic effect (Gillbro and Olsson, 2011).  
Creams containing clobetasol propionate are drug products that are normally sold in several countries to 
treat various skin conditions. These products are unfortunately diverted from their normal use and used 
by women for skin whitening. They have anti-inflammatory, antipruritic, and vasoconstrictive properties 
and are known to reduce production of the arachidonic acid and of prostaglandin (Hammarstrom et al., 
1977).  The mechanism by which the topical steroids lighten the skin, in general, is unclear (Dadzie and 
Petit, 2009). However, it seems that these molecules have a strong affinity for the specific receptors for 
the keratinocytes and the melanocytes causing a depigmenting effect (Roguedas-Contios and Garcia-Le 
Gal, 2005). They may have many adverse effects on user health (Fanny et al., 2014, Sene et al., 2008, 
Mahe et al., 2007).  
Several standards have been established for these toxic agents by international and national 
organizations. In the case of hydroquinone products, they are officially banned in Canada and the 
European Union (EU, 2009, Hc-sc.gc.ca, 2015) but are still allowed in the United States and several 
countries of West Africa at a concentration up to 1.5 to 2% (US FDA, 2016, Ivory Coast, 2015). 
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However, mercury is banned in lightening products sold in the European Union and of Ivory Coast but 
allowed in cosmetics sold in Canada and the United States in concentrations up to 1µg/g (Hc-sc.gc.ca, 
2016, US FDA, 2016). Finally, most regulations consider that the standard limit of clobetasol propionate 
in dermatological preparations is 0.05% (US FDA, w/w) when it is sold with prescription.  
The production, distribution and sale of these products normally regulated in several countries is 
nevertheless carried by informal channels making difficult the compliance with recommended standards 
(Bocca et al., 2014, Glenn, 2008). Many of these products are readily available on streets, markets, and 
in non-pharmaceutical shops in West Africa and North American cities with West African communities 
where control of these products by local health authorities remains difficult (Hamann et al., 2014, 
Adepoju-Bello et al., 2012, Peregrino et al., 2011, Glenn, 2008, Voegborlo et al., 2008). Because these 
products are popular and can pose many problems on user’s health, it is important to establish if these 
standard limits are respected in skin lightening products sold in countries around the world, especially in 
West Africa where there are several cases of adverse effects associated with topical application of these 
products such as nephropathy and exogenous ochronose (Levitt, 2007, US FDA, 2009). 
 In this study, we focused on two geographical regions where females use these products and we 
determined mercury, hydroquinone, and clobetasol propionate in a wide variety of skin lightening 
creams and soaps. Specifically, we collected products from various local markets in West Africa and in 
Montreal (Canada), a large North American city with an important West African population. In Africa, 
we focused on Benin, Ivory Coast, Mali and Senegal. Our main objective was to determine the 
concentrations of different active ingredients commonly found in skin lightening products in West 
Africa and Canada, and to compare them with regulatory guidelines. We further tested if concentrations 
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of active ingredients stated on product labels are accurate and therefore correctly inform the consumers 
on the risk associated with the product. 
 
2. Materials and methods  
2.1. Sampling of skin lightening personal care products 
A total of 191 skin-lightening creams and soaps (98 creams and 93 soaps) commonly used by women 
were purchased from the local markets of West Africa and Canada. In West Africa, we collected the 
products in the largest markets of the cities of Cotonou (Benin) in August 2013, and Bamako (Mali), 
Dakar (Senegal) and Abidjan (Ivory Coast) in August-September 2014. In Canada, we bought imported 
products in June 2013 in a dozen of small ethnic beauty shops located in the city of Montreal. Most of 
the products analysed were imported from different countries of Asia (Malaysia, Thailand and India), 
EU (France, Italy, UK and Germany), and of North America (USA, Dominican Republic), whereas 
some were locally imported from Africa (Democratic Republic of the Congo, Ivory Coast). 
We analyzed mercury in all soaps and creams of all countries, namely in 6 soaps and 18 creams 
purchased in Benin, in 27 soaps and 25 creams purchased in Ivory Coast, in 20 soaps and 12 creams 
purchased in Mali, in 23 soaps and 25 creams purchased in Senegal and in 17 soaps and 18 creams 
purchased in Montreal, Canada (Figure 2a).  
We measured hydroquinone in all creams of all countries.  Similarly, we measured clobetasol propionate 
in all creams except in those containing hydroquinone exceeding 2% because we did not expect the 
simultaneous presence of hydroquinone and clobetasol propionate in the same cream at high 
concentrations.  We did not measure hydroquinone or clobetasol propionate in soaps because these 
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ingredients are not expected in lightening soaps (Groupe Thématique 'Peau Noire' de la Société 
Française de Dermatologie, 2011). 
2.2. Mercury analyses 
Cream and soap samples were analyzed using an automatic MERCURY SP-3D analyzer (Nippon 
Instruments, Osaka, Japan) in accordance with USEPA method 7473. After combustion at 700oC, 
mercury was converted catalytically to elemental mercury. Following dual gold amalgamation, the 
quantity of mercury was measured by cold vapor atomic absorption at a wavelength of 253.7 nm. 
Between 10 to 100 mg of soap and cream samples were placed on a layer of an additive (mixture of 
sodium carbonate and calcium hydroxide; EMD Chemicals, NJ, USA) in a ceramic boat as suggested by 
the supplier. The sample was then covered with a layer of the same additive. A layer of aluminum oxide 
(Al2O3; Acros Organics) was placed over the sodium carbonate–calcium hydroxide layer. The aluminum 
oxide layer was covered with another layer of the additive. The boat was then transferred manually into 
the ceramic thermal decomposition tube. After feeding the samples, all operations from the sample 
decomposition to the mercury detection were automatically carried out with SP-3D mercury analyzer 
system. Reference materials (Tort-2, 270 ± 60 ng/g; Dorm-4, 410 ± 55 ng/g; National Research Council 
of Canada, Ottawa, Canada) were analyzed every 10 samples to ensure reproducibility and to assess 
analytical quality. The analyses were accepted when measurements of certified reference materials were 
in the certified range. Mean concentrations of certified materials were 284 ± 1 (n = 5) and 383 ± 2 (n = 






2.3. Hydroquinone analyses 
To extract hydroquinone, we accurately weighed 0.050 g of skin lightening cream and added 10 mL of 
ethanol. Samples were incubated in a water bath for 20 min at 50oC, and let to cool down before analysis 
(Al-Saleh et al., 2012). We determined hydroquinone by a high-performance liquid chromatography 
(HPLC) method slightly modified from Al-Saleh et al. (2012) (HPLC with a UV-DAD detector, Agilent 
1200, Santa Clara, US). Briefly, 1 mL of each sample was filtered through a 0.45 µm syringe filter and 
20 µL were injected into the HPLC. Hydroquinone was separated on 5-µm particle 4.6 x 150 mm, 
Zorbax eclipse XDB-C18 column. Isocratic system was used with a mobile phase (90:10 water: 
acetonitrile) prepared daily and degassed prior to use. Detection was done at a wavelength of 289 nm. 
Retention time was 2.7 min and total run time was 6 min. A stock solution of 1 mg mL-1 hydroquinone 
was prepared in methanol. Working calibration curves were prepared by spiking 0.05 g of cream with 
different volumes of stock solution. Hydroquinone standard was purchased from Sigma-Aldrich ≥ 99% 
(Saint Louis, US). The analytical recoveries were 102%, 101%, 98% and 98% with RSDs of 1.5%, 
0.58%, 1.53% and 2%, respectively for four spiked cream samples. 
2.4. Clobetasol propionate analyses 
Clobetasol propionate (CP) was analyzed according to Nam et al. (2011). Briefly, approximately 2 g of 
cream was mixed to attain a homogeneous mixture, and 1 g was accurately weighed into a 10 mL 
volumetric flask. It was then diluted with 10 mL acetonitrile, shaken vigorously and precipitated by 
centrifugation, filtered through a 0.45 µm syringe filter, and transferred into a 1-mL vial. Instrumental 
and analytical conditions were the same as described by Nam et al. (2011) using HPLC with UV-DAD 
detector (Agilent 1200, Santa Clara, US). Separation was carried out on ZORBAX1 Eclipse XDB-C18, 
a 5 mm C18 column (150 mm x 4.6 mm, Agilent Technologies, USA), with a flow rate of 1 mL min-1, 
	
	 10	
column temperature of 27oC, injection volume of 10 µl, and a total running time of 25 min. HPLC 
method for separation of standards and samples were modified from Nam et al. (2011) as follows. The 
elution was carried out using mobile phases A (0.1% phosphoric acid in water) and B (acetonitrile) at 
240 nm. UV scan mode, which ranged from 210 to 400, was used. Standards and samples were 
separated with solution B. The calibration curve was prepared for clobetasol propionate obtained from 
Sigma Aldrich ≥ 98% (FLUKA, US) by adding suitable amounts of standard stock solution to blank 
samples in triplicate. The analytical recoveries were 100%, 99% and 99% with RSDs of 1.5%, 2.1%, 
and 1.5% respectively for tree spiked cream samples. 
2.5. Determination of impurities 
Mercury and hydroquinone are naturally occurring agents. They are banned in some countries but 
regulations do not directly consider natural impurities. It is important to assess if the concentrations that 
we measured resulted from acceptable impurities or voluntary addition by the manufacturer. We plotted 
all measured mercury and hydroquinone concentrations in decreasing order (Suppl. Info: Fig. S2.1 to 
S2.3.). We drew a line at the breaking point where levels started to depart rapidly from background 
concentrations, and considered that levels below this point constituted acceptable impurities (Table S2). 
Products with such acceptable impurities were considered as not contravening to the ban. 
2.6. Statistical analyses 
Statistical analyses were done with R 2.15.0. Differences between concentrations of active ingredients in 
products from West Africa and Canada were assessed using Kruskal−Wallis nonparametric tests 
followed by Tukey's multiple comparisons test (Scherrer, 1984). Log10 transformation was used to 
perform boxplot for mercury in soap and cream because of some extreme values. A statistical 
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probability level of p < 0.05 was considered statistically significant for all comparisons. We also 
calculated the proportions of products (soaps or creams) that exceeded regulatory limits. 
 
3. Results  
 
3.1 Concentrations of active ingredients in soaps and creams 
3.1.1 Mercury concentrations in soaps and creams 
We analyzed mercury in 93 lightening soaps and 98 creams. Levels of mercury in soaps ranged from 
5.45 x 10-5 to 8370 µg/g with a mean of 349 µg/g (Figure 1a). Median mercury concentrations in soaps 
from Benin, Ivory Coast and Canada were higher than those from Senegal and Mali. Maximum soap 
mercury concentrations in one country in West Africa (Benin) were ~8000-times higher than the US 
FDA limit. When considering mercury ban in lightening products with a threshold impurity limit of 0.6 
µg/kg (see section 2.5.), we observed that all soaps purchased in Benin and Canada exceeded guidelines. 
Overall, 65.6% (61/93) of all soaps analyzed from all countries exceed 0.6 µg/kg. Kruskal–Wallis test 
on mercury concentration in soaps revealed significant differences among mercury concentrations in 
soaps by country (Table S1). According to subsequent Tukey HSD posthoc tests, mercury 
concentrations in soaps purchased from Benin were significantly greater than in those purchased in other 
countries. 
In creams, levels of mercury ranged from 4.8 x 10-5 to 0.914 µg/g and were all below the US FDA 
standard limit (1 µg/g). All mercury concentrations in creams from Benin and Canada exceeded the 
impurity threshold of 0.6 µg/kg, with mercury concentrations in creams from Benin (between 1.80 x 10-3 
and 4.25 x 10-2 µg/g) higher than in those from Canada (between 6.37 x 10-4 and 9.85 x 10-3 µg/g) except 
for one cream purchased in Canada that had a high concentration of mercury (0.914 µg/g). Creams 
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purchased in Ivory Coast, Mali and Senegal had mercury concentrations below 0.6 µg/kg except for two 
creams from Senegal (Figure 1b). 
 
3.1.2. Hydroquinone concentrations in creams 
Among the 98 skin-lightning creams, levels of hydroquinone in creams ranged from 0 to 6% (w/w) with 
a mean of 1.2% (w/w). Median in Mali was ~2-times higher than the US FDA limit of 2% (w/w) 
(Figure 1c). Levels of hydroquinone in creams bought in Mali were significantly higher than creams 
bought in Ivory Coast, Senegal and Canada (Table S1, Tukey’s post hoc test; P<0.05). In Benin and 
Mali, hydroquinone concentrations exceeded US FDA standards in over 44% of creams (Figure 2b).	
When considering European Union legislation that bans hydroquinone in skin lightening creams, we 
observe that 38% (37/98) of all creams analyzed exceed 0.5% (w/w) which was defined as the 








Boxplot showing (in µg Hg/kg) minimum, median and maximum concentrations, and 25th, 75th 
percentiles of log10 (Hg) for mercury in soaps (a) and creams (b) in different countries in West Africa 
and Canada. Dotted line represents the US FDA threshold of 1 µg Hg /kg. Boxplot showing (in %, w/w) 
minimum, median and maximum values and 25th, 75th percentiles of % (w/w) for hydroquinone in 
creams (c) in different countries in West Africa and Canada. Dotted line represents the US FDA 
threshold of 2% hydroquinone, w/w. Boxplot showing (in % w/w) minimum, median and maximum 
values, and 25th, 75th percentiles of % (w/w) for clobetasol propionate in creams (d) in different 
countries in West Africa and Canada. Dotted lines represent the US FDA threshold of 0.05% clobetasol 
propionate, w/w. Solid lines represent acceptable impurity thresholds (see section 2.5.).  
 
3.1.3. Clobetasol propionate concentrations in creams 
Creams containing clobetasol propionate at 0.05% (w/w) are drug products and are banned from sale 
without medical prescription. In our study, when considering the bans of these products, clobetasol 
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propionate was detected in 39% (38/98) of creams with a mean of 0.0265% (w/w). However, 20% 
(20/98) of creams exceeded US FDA standards limits of 0.05%, (w/w) when we ignored their ban. 
Levels of clobetasol propionate in creams bought in Senegal were significantly higher than in creams 
bought in Mali and Canada (Table S1, Tukey’s post hoc test; P<0.05). The median in Senegal was ~2-
times higher than in Benin (Figure 1d). Exceedance of US FDA limits (when creams are supposedly 
sold with medical prescription) was more common in creams purchased from West African countries 
than in those purchased in Canada, with 22.5% of creams exceeding 0.05%; w/w limit in West Africa (5 






 Histograms showing (a) the number of creams and soaps bought by country and (b) frequencies of 
exceeded regulatory guidelines by country, using US FDA standards not considering bans of PC. 
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3.2. Accuracy of labeling information 
In order to verify if concentrations of active ingredients listed on the labels are similar to those 
measured, we have selected soaps and creams for which manufacturers stated concentrations on the 
labels. For Hg, 2.6% (5/191) of products reported its presence on labels (between 1.2 to 2% mercury 
iodide, i.e. 5280 to 8800 µg/g); for hydroquinone, 17% of creams (17/98) listed concentrations of 1.2 to 
2% on labels; for clobetasol propionate, 28% (27/98) of creams reported concentrations of 0.05% on the 
packaging.  
For all three ingredients, we defined a gray area that represents a margin of ± 10% confidence around 
the declared value. When considering this gray area, we observe on Figure 3 that there was no 
relationship between concentrations mentioned on packaging and those measured by us in several 
products regardless of the country of purchase, indicating that labels inaccurately report concentrations 
of some potentially toxic ingredients (Figure 3a, 3b & 3c). 
Regarding mercury, 5 soaps purchased from Ivory Coast and Canada report presence of this ingredient 
on theirs labels at concentrations between 1.2 to 2% mercury iodide. However, mercury concentrations 
that we measured in these products were below values indicated on the labels (figure 3a). Moreover, we 
surprisingly measured high mercury concentrations (ranging from 8370 to 3520 µg/g) in 5 other soaps 
purchased from West Africa that did not indicate the presence of Hg on their packaging. 
In the case of hydroquinone, several products stating concentration of 2% on their labels had 
concentrations up to 5.5%. Among these products, 82% of products (9 products of 11) purchased from 
West Africa (Benin and Mali) had concentrations of hydroquinone that exceeded by 2 fold the 
concentrations shown on labels (Figure 3b). When considering the gray area, 50% of products 
	
	 17	
purchased from Canada had hydroquinone concentration similar to declared values, and 50% had levels 
1.5 to 2 times higher than stated on the labels (Figure 3b). 
For clobetasol propionate, products labelled as containing 0.05% clobetasol propionate had 
concentrations of up to 0.08%. 65% of products (15 products of 23) purchased from West Africa (Benin, 
Ivory Coast and Senegal) had levels exceeding those reported on labels. However, when considering the 
gray area, most of clobetasol propionate concentrations measured were around the declared value except 







Scatter plot showing correlations between mercury concentrations observed on packaging of the labels 
and concentrations of (a) mercury concentrations in creams and soaps, (b) hydroquinone in creams, (c) 
clobetasol propionate in creams. The gray area represents a margin of ± 10% confidence around the 


















4.1. Are concentrations of toxic ingredients found in skin-lightening products of concern? 
In order to put our results in a broader context, we compared levels of toxic ingredients in skin-
lightening products to limits imposed by four regulatory agencies, namely the US FDA, Health Canada, 
the Regulation (EC) 1223/2009 and the Directive 76/768/EEC of the European Union and the Ministry 
of Commerce of the Ivory Coast (Table 1). In some cases, an ingredient was completely banned from 
sale without medical prescription; in these instances, all products containing the ingredient were 
considered as exceeding the limits; however, since Hg and hydroquinone are naturally occurring 
ingredients, we set a lower limit to distinguish between natural impurities and voluntary addition. A 
product was only considered as exceeding the limit in the case of banned substances if the ingredient 
exceeded the levels set for voluntary addition (Table S2). 
Using this approach, we determined that 68 to 84% of all creams exceeded safety limits of at least one of 
the three toxic ingredients (Table 1). When ignoring the bans of some ingredients in products sold 
without prescription, 50 to 74% of creams exceeded the guidelines. We conclude that there is very 
important health risk associated with the sale of skin-lightening creams, since a large proportion of them 
exceeded national guidelines of multiple countries.  
Whereas several studies have measured only one ingredient in lightening products (e.g. mercury), our 
approach of integrating simultaneously three types of toxic agents allowed for a more general 
appreciation of their health risks (see Table S5 in supplementary information for details about 
comparisons with guidelines by other authors). 
The guidelines recommended by the US FDA to limit the presence of toxic agents in lightening products 
are used in many countries such as China and Mexico (Wang and Zhang, 2015, Peregrino et al., 2011). 
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These standards are less stringent than those of the European Union that totally prohibit mercury, 
hydroquinone and clobetasol propionate in lightening products. They are also less stringent than those of 
some Western African countries such as the Ivory Coast that totally prohibit mercury and clobetasol 
propionate in lightening products. The stricter regulations of EU compared to US FDA led to 24% 
increase in the number of creams, and 58% of soaps exceeding standards.  
This study shows that the problem of the presence of toxic active agents at high concentrations in 
lightening products arises in all the countries we studied. Other studies have also reported that many 
lightening products sold in certain countries such as Ivory Coast, Mali, Senegal, and other lightening 
products used in some Canadian immigrant communities, contain many toxic active agents (Hamann et 
al., 2014, Mistry et al., 2011, Uram et al., 2010, Ake et al., 2007, Mahe et al., 2007, Mahé et al., 2004, 
Del Giudice et al., 2003, Mahe et al., 2003, Mahé et al., 1993). Several of these studies have found very 
high concentrations of mercury in creams and soaps; notably, soaps purchased in Tanzania stand out for 
unknown reasons compared to those from other countries (Table 2). Other studies are based on 
concentrations mentioned on packaging of products to show that hydroquinone and clobetasol 
propionate were also in high concentrations in a wide variety of creams sold in West Africa, including 
Mali and Senegal  (Mahe et al., 2007, Mahe et al., 2003, Mahé et al., 1993).  
Although we found low concentrations of mercury in creams (below 1µg/g), our study clearly confirms 
the presence of mercury in soaps and of hydroquinone and clobetasol propionate in lightening creams at 
high concentrations. We identify hydroquinone and clobetasol propionate as key emerging toxic 
ingredients, although they are rarely analyzed when compared to Hg. We suggest that these two 
ingredients be prioritized for future research in countries where they are now documented to be 
prevalent in products, i.e. all countries included in this study.  
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We have never observed simultaneously high concentrations of three ingredients in the same product 
when considering US FDA limits (Table S4). These results are not consistent with a study conducted by 
Maneli et al. (2015) in South Africa that measured simultaneously mercury, hydroquinone and 
clobetasol propionate in two lightening products, although concentrations of hydroquinone and 
clobetasol propionate detected in these products were low compare to those of  mercury. As all active 
agents can act on melanin formation and transfer, we do not expect to find more than one toxic agent in 
a given lightening product. However, this study was conducted in South Africa, while our products came 
from West Africa and Canada. It is possible that market pressures, constraints and controls are different 
in South Africa compared to West Africa. 
4.2. Are labels of skin-lightening product accurate? 
In order to verify the compliance of information mentioned on the labels of lightening products, we 
determined relationships between the concentrations of active ingredient stated on the labels of the 
products analyzed and the concentrations we measured. Overall, we found that most of manufacturers do 
not inform correctly consumers on the exact concentrations of active ingredients. These observations 
suggest an insufficient control by local authorities of products sold in large markets in West Africa and 
small ethnic beauty shops in Canada. We suggest the strengthening of regulation and of control on 
cosmetic products in order to limit exposure of the population to toxic ingredients and to more 







The results of our study confirm that mercury, hydroquinone and clobetasol propionate are still used in 
relatively high concentrations in skin lightening products. Soaps were more concentrated in mercury 
compared to creams which were much more concentrated in hydroquinone and clobetasol propionate. 
Several products which do not indicate the presence of mercury, hydroquinone and clobetasol 
propionate on their labels also had high concentrations of these ingredients. Because the levels of 
mercury, hydroquinone and clobetasol propionate detected in products often exceed regulatory 
guidelines, further study should be undertaken to better document the effect of these products on the 
health of consumers. With the recent advances in the relationships between microbiomes and human 
health, it would be particularly relevant to explore the effect of these personal care products on the skin 
microbiome, and how this can alter human health. The availability of contaminated products and their 
inaccurate labeling lead us to suggest that regulations should be more strictly enforced in countries 
where these products are sold. 
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Table 1: Frequencies of exceedance of regulatory guidelines for all ingredients tested according to 
different standards and considering the ban of non-prescription products. Definition of categories: 
considering bans: Exceedance frequency of all ingredients considering the ban of a toxic ingredient in 
non-prescription products; not considering bans: Exceedance frequency of all ingredients considering 
the thresholds used for products available with a medical prescription. 
   Categories     For all 
creams 
For all soaps For all products 
(creams + soaps) 
US FDA limit considering bans For each ingredient Hg 0 (0/98) 7.5 (7/93)   
HQ 29.6 (29/98) 0 (0/93)   
PC 38.7 (38/98) 0 (0/93)   
For all ingredient1 Hg + HQ + PC 68.3 (67/98) 7.5 (7/93) 38.7 (74/191) 
not considering bans For each ingredient Hg 0 (0/98) 7.5 (7/93)   
HQ 29.6 (29/98) 0 (0/93)   
PC 20.4 (20/98) 0 (0/93)   
For all ingredient Hg + HQ + PC 50 (49/98) 7.5 (7/93) 29.3 (56/191) 
Health Canada limit considering bans For each ingredient Hg 0 (0/98) 7.5 (7/93)   
HQ 37.7 (38/98) 0 (0/93)   
PC 38.7(38/98) 0 (0/93)   
For all ingredient Hg + HQ + PC 74.4 (73/98) 7.5 (7/93) 41.8 (80/191) 
not considering bans For each ingredient Hg 0 (0/98) 7.5 (7/93)   
HQ 38.7 (38/98) 0 (0/93)   
PC 20.4 (20/98) 0 (0/93)   
For all ingredient Hg + HQ + PC 58.1 (57/98) 7.5 (7/93) 33.5 (64/191) 
EU limit considering bans For each ingredient Hg 38.7 (38/98) 65.6 (61/93)   
HQ 37.7 (37/98) 0 (0/93)   
PC 38.7 (38/98) 0 (0/93)   
For all ingredient Hg + HQ + PC 84.6 (83/98) 65.6 (61/93) 75.3 (144/191) 
not considering bans For each ingredient Hg 38.7 (38/98) 65.6 (61/93)   
HQ 37.7 (37/98) 0 (0/93)   
PC 20.4 (20/98) 0 (0/93)   
For all ingredient Hg + HQ + PC 74.4 (73/98) 65.6 (61/93) 70.1 (134/191) 
Ivory Coast limit considering bans For each ingredient Hg 38.7 (38/98) 65.6 (61/93)   
HQ 29.6 (29/98) 0 (0/93)   
PC 38.7 (38/98) 0 (0/93)   
	
	 24	
For all ingredient Hg + HQ + PC 82.6 (81/98) 65.6 (61/93) 74.3 (142/191) 
not considering bans For each ingredient Hg 38.7 (38/98) 65.6 (61/93)   
HQ 29.6 (29/98) 0 (0/93)   
PC 20.4 (20/98) 0 (0/93)   
For all ingredient Hg + HQ + PC 70.4 (69/98) 65.6 (61/93) 68 (130/191) 
 
1 See Table S3 for calculations of frequencies of exceeding regulatory guidelines for all ingredients 




Table 2: Concentration of mercury, hydroquinone and clobetasol propionate in lightening products 
purchased from various countries. 
Region/Country of 
products purchase 







Africa           
   Benin 2.36x10-2 - 8.37x103 1.80x10-3- 6.86x10-2 0-5.73 0-0.052 Our study 
   Ivory Coast 2.42x10-4 - 4.48x103 6.30x10-5 - 3.39x10-4 0-3.95 0-0 0.081 Our study 
   Mali 5.45x10-5 - 6.65x10-3 4.80x10-5 - 4.13x10-4 0-6.02 0-0.009 Our study 
   Senegal 2.98x10-5 - 5.39x10-3 5.8x10-5 - 3.47x10-2 0-4.56 0-0 0.086 Our study 
   Nigeria   9 x10-3 – 2.07 x10-1     (Adepoju-Bello et al., 
2012) 
   Senegal   <7 x10-3     (Uram et al., 2010) 
   Kenya   <7 x10-3     (Uram et al., 2010) 
   Kenya 1.1x10-1 – 7.4 x103       (Harada et al., 2001) 
   Ghana   <7x10-3-7.9 x10-2     (Voegborlo et al., 
2008) 
   South Africa* 1.9x103 ± 10.00 3x101 ± 8.68 – 2.3x103 ± 6.67 < 2   (Maneli et al., 2015) 
   Tanzania 6.2x103-7.4 x103  <7      (Glahder et al., 1999)  
Middle East           
   Saudi Arabia   6.3710-1 – 2.745      (Alqadami et al., 2013) 
   Saudi Arabia   0 - 3.14x103     (Al-Saleh et al., 2012) 
   Saudi Arabia   1.02 x10-1 - 7.75 x10-1     (Al-Saleh et al., 2005) 
   Saudi Arabia   0 – 5.65 x103     (al-Saleh and al-Doush, 
1997) 
   Saudi Arabia     0 - 4,186 ± 
0.195 
  (Al-Saleh et al., 2012) 
North America           
   Canada 2.27x10-3 - 7.35x10-2 6.37 x 10-4 - 0.914 0 - 3.01 0 - 0.063 Our study 
   Mexico    <5 x10-3- 8.78 x102  ±1.15 x102     (Peregrino et al., 2011) 
   Mexico   <7 x10-3 -1.325 x103     (Uram et al., 2010) 
   USA (Online)   1.044 ±121 – 9.603 x103±1.14 x102     (Hamann et al., 2014) 
   USA   1.354 x101±6.07 x102 – 3.291x 
101±2.127x103 
    (Hamann et al., 2014) 
   USA 4.77-4.38x102 3.37- 4.160 x101      (McKelvey et al., 2011) 
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Table S1: Kruskal−Wallis nonparametric and Tukey's multiple comparisons tests on concentrations of 




Kruskal Wallis test Tukey HSD Post hoc test 
Chi-squared df P-value Class Country Mean 
[Hg]soap 51.171 4 2.056e-10 
a Benin 2727000 µg/Kg 
b Ivory Coast 596300 µg/Kg 
b Canada 22.78 µg/Kg 
b Senegal 1.232 µg/Kg 
b Mali 0.884 µg/Kg 
[Hg]cream 69.663 4 2.674e-14 
a Canada 53.22 µg/Kg 
a Benin 10.71 µg/Kg 
a Senegal 0.336 µg/Kg 
a Ivory Coast 0.187 µg/Kg 
a Mali 0.129 µg/Kg 
[HQ]cream 24.243 4 7.141e-05 
a Mali 3.272 % 
ab Benin 2.024 % 
b Canada 0.953 % 
b Senegal 0.560 % 
b Ivory Coast 0.508 % 
[PC]cream 11.041 4 0.026 
a Senegal 0.043 % 
ab Ivory Coast 0.023 % 
ab Benin 0.017% 
b Canada 0.013 % 
b Mali 0.003 % 
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Table S2: Acceptable impurities in the case of banned substances*  
Ingredients Acceptable impurities 
Hg in soaps 0.6 µg/kg 
Hg in creams 0.6 µg/kg 
HQ in creams 0.5% 
* These impurity limits were defined by us from our data, for legislations which completely ban these 
ingredients in cosmetics	
 










Figure S2.3: Determination of acceptable impurities in the case that HQ is banned in creams
 
Table S3: Threshold values, for different regulations, when considering acceptable impurities. 	
     
   Categories PC HQ Hg 
US FDA limit considering bans 0% 2% 1µg/g  
  not considering bans 0.05% 2% 1µg/g 
          
Heath Canada limit considering bans 0% 0.5% 1µg/g  
  not considering bans 0.05% 0.5% 1µg/g  
          
EU limit considering bans 0% 0.5% 0.6µg/kg  
  not considering bans 0.05% 0.5% 0.6µg/kg 
          
Ivory Coast limit considering bans 0% 2% 0.6µg/kg  
  not considering bans 0.05% 2% 0.6µg/g  
 
1 Each product (cream or soap) that exceeds standard was counted once only. 
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Table S4: Frequencies of exceedance of guidelines by more than one ingredient in a given product. 	
   Categories % of all same 
creams excess 
both Hg, HQ 
and PC 
standards 
% of all same 
creams excess 
both Hg and 
HQ standards 
% of all same 
creams excess 
both Hg and 
PC standards 
% of all same 
creams excess 
both HQ and 
PC standards 
US FDA limit considering bans 0 0 0 0  
  not considering 
bans 
0 0 0 0 
            
Heath Canada 
limit 
considering bans 0 0 0 3 (3/98) 
  not considering 
bans 
0 0 0 1 (1/98) 
            
EU limit considering bans 0  19.3 (19/98) 9.1 (9/98) 3 (3/98) 
  not considering 
bans 
0 19.3 (19/98) 3 (3/98) 1 (1/98) 
            
Ivory Coast 
limit 
considering bans 0 15.3 (15/98) 9.1 (9/98) 0 
  not considering 
bans 




Table S5: Percentage of products (creams or soaps) exceeding regulatory guidelines for Hg, of HQ or of 
PC published in other studies. 
	
  % in creams % in soaps % in (creams + soaps) References 
[Hg] > 1ppm 0 (0/146)     (Wang and Zhang, 2015) 
64.7 (22/34)     (Alqadami et al., 2013) 
8.7 (2/33)     (Al-Saleh et al., 2012) 
37.5 (6/16)     (Peregrino et al., 2011) 
47.36 (9/19)     (Murphy et al., 2009) 
100 (21/21)     (Sin and Tsang, 2003) 
41.4 (12/29)     (Maneli et al., 2015) 
45 (17/38)     (al-Saleh and al-Doush, 1997) 
0 (0/98) 7.52 (7/93) 3.6 (7/191) Our study 
47(8/17) 100 (2/2) 52.6 (10/19) (McKelvey et al., 2011) 
  57.14 (8/14)   (Harada et al., 2001) 
  100 (3/3)   (Glahder et al., 1999) 
[Hg] > 10,000ppm 45% (247/549)      (Hamann et al., 2014) 
          
[HQ] > 2% 29.5 (29/98)     Our study 
[HQ] > 0,5% 37.7 (37/98)     Our study 
[HQ] > 0,5% 12 (19/163)     (Desmedt et al., 2014) 
[HQ] > 1% 18.5 (6/33)     (Al-Saleh et al., 2012) 
[HQ] > 0,5% 100 (10/10)     (Odumosu and Ekwe, 2010) 
[HQ] > 0,5% 37.9 (11/29)     (Maneli et al., 2015) 
          
[PC] > 0,05% 20.4 (20/98)     Our study 
[PC] > 0% 39.7 (39/98)     Our study 
[PC] > 0% 40 (65/163)     (Desmedt et al., 2014) 
[PC] > 0% 92.2 (83/90)     (Ake et al., 2007) 
[PC] > 0,05% 74.3 (62/83)     (Ake et al., 2007) 
[PC] > 0% 31 (9/29)     (Maneli et al., 2015) 
     
% of all products considered as illegal  References 
59 (Desmedt et al., 2014) 
75.9 (Maneli et al., 2015) 
	
 
